Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S5
Saturation profiling of drug-resistant genetic variants using prime editing.
Kim Y et al.
Nature Biotechnology, 2025
HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer.
Zhan J et al.
Journal of Translational Medicine, 2025
A rare epidermal growth factor receptor T790M/cis-C797S/L718Q compound mutation in a lung adenocarcinoma patient who did not derive any benefit from combination therapy with afatinib and bevacizumab.
Meng X et al.
Sage Open Medical Case Reports, 2025
39963146 (PubMed )
Supplement: sj-xlsx-2-sco-10.1177_2050313X251319381.xlsx › Sheet1
Efficacy and tolerability of osimertinib with dabrafenib and trametinib in BRAF V600E acquired EGFR-mutant non-small cell lung cancer: a case series.
Lu K et al.
Journal of Thoracic Disease, 2024
Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S et al.
Cancer Medicine, 2024
38572952 (PubMed )
Supplement: CAM4-13-e7162-s003.xlsx › DNA_mutations
Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y et al.
Scientific Reports, 2024
38238401 (PubMed )
Supplement: 41598_2024_52006_MOESM5_ESM.xlsx › combie_list
The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib.
Yang LL et al.
Translational Cancer Research, 2023
High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib.
Osoegawa A et al.
Jto Clinical and Research Reports, 2021
The next tier of EGFR resistance mutations in lung cancer.
Tumbrink HL et al.
Oncogene, 2021
Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment.
Li HS et al.
Frontiers in Oncology, 2021
ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.
Kiavue N et al.
Oncogene, 2020
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort.
Fairclough SR et al.
Experimental Hematology & Oncology, 2019
Protein-structure-guided discovery of functional mutations across 19 cancer types.
Niu B et al.
Nature Genetics, 2016
Select a paper to view details